Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab

Acta Derm Venereol. 2018 Jan 12;98(1):151-152. doi: 10.2340/00015555-2794.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Hidradenitis Suppurativa / diagnosis
  • Hidradenitis Suppurativa / drug therapy*
  • Hidradenitis Suppurativa / immunology
  • Humans
  • Interleukin-17 / antagonists & inhibitors*
  • Interleukin-17 / immunology
  • Male
  • Remission Induction
  • Severity of Illness Index
  • Treatment Outcome
  • Young Adult

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • IL17A protein, human
  • Interleukin-17
  • secukinumab